What MetLife’s Recent Share Performance Tells Investors

MetLife (MET) has quietly moved higher in recent weeks, with the share price up around 4.8% over the past month and 5.5% over the past 3 months, drawing fresh attention from income and value focused investors.

Set against a small year to date share price return decline of 1.4% and a 1 year total shareholder return decline of 1.4%, the recent 30 and 90 day share price gains suggest momentum has picked up again from a relatively flat 12 month base.

If this insurance move has you thinking about other areas of the market, it could be a good moment to scan our list of 22 top founder-led companies as a fresh source of ideas.

With MetLife trading at $79.22, at a discount to an average analyst price target of $91.73 and an estimated intrinsic value gap of roughly 54%, you have to ask: Is there real value here, or is the market already baking in future growth?

Most Popular Narrative: 14.8% Undervalued

MetLife’s latest fair value narrative sits at $92.93 per share versus the current $79.22 price, putting a spotlight on what is driving that gap.

Strategic expansion of asset-light, fee-generating businesses (like employee benefits, asset management, and longevity reinsurance), combined with disciplined capital management, supports higher return on equity and more consistent, less capital-intensive earnings growth.

Wondering what kind of revenue path and margin profile could justify that fair value and still assume a lower earnings multiple than many peers? The full narrative lays out a detailed earnings roadmap, links it to long term retirement income demand, and builds a case around capital efficient growth rather than simple premium volume. Curious which specific profit and balance sheet assumptions sit behind that $92.93 figure and how much execution room they leave? The answers are in the projections, not in the headline price.

Result: Fair Value of $92.93 (UNDERVALUED)

However, this depends on investment returns and credit quality holding up, with weaker yields or commercial mortgage losses both capable of putting real pressure on earnings and capital.

Another Angle On MetLife’s Valuation

Our DCF model suggests a fair value of $173.32 per share, which is far above the current $79.22 price and even the $92.93 narrative fair value. That kind of gap can reflect either a genuine long term opportunity or very optimistic cash flow assumptions. Which side do you think is more realistic?

Next Steps

Seeing both upside and risk in the story so far, it makes sense to move quickly and test the assumptions yourself using our breakdown of 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If MetLife has sharpened your thinking, do not stop here. Use this momentum to size up a wider set of opportunities before the market moves on.

• Spot potential value candidates early by scanning our 53 high quality undervalued stocks that pair quality fundamentals with prices that may not fully reflect them yet.
• Strengthen your income shortlist with our hand picked 13 dividend fortresses that focus on higher yields backed by business performance.
• Tighten your risk profile by checking companies in our 80 resilient stocks with low risk scores where balance sheets and track records help keep surprises in check.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.